TheVentureCity

Third Rock Ventures is a Boston-based life sciences venture capital firm that co-founds and builds biopharmaceutical companies in partnership with leading scientists and academic medical centres, investing from seed through Series A and Series B stages with initial checks from $10 million to $50 million. The firm creates companies from the ground up, identifying breakthrough scientific insights from academic research and translating them into commercial biopharmaceutical enterprises. Portfolio companies include Blueprint Medicines, the precision therapy company; Editas Medicine, the CRISPR gene editing therapy company; Karuna Therapeutics, the clinical-stage company developing treatments for schizophrenia acquired by Bristol-Myers Squibb for $14 billion; and Relay Therapeutics, the computational drug discovery company. Beyond its original investments, the portfolio includes additional biopharmaceutical companies co-founded through Third Rock.